Skip to main content
. Author manuscript; available in PMC: 2018 Nov 13.
Published in final edited form as: Clin Cancer Drugs. 2018;5(1):28–41. doi: 10.2174/2212697X05666180418145601

Table 1.

Migration analysis of MDA-MB-231 cells after the treatment with 5-LOX inhibitors

Treatment MDA-MB-231, 0 h MDA-MB-231, 24 h
Mean ± SD Mean ±SD
Control 2.3 ± 1.3 79 ± 7.6
AA 3.4 ± 2.2 119.7 ±18.9
NDGA 2±1.4 9 ± 1.7
AA + NDGA 4±1.5 84.7±18.9
Zil 2.2 ± 1.1 40 ± 5.2
AA + Zil 2.3 ± 1 69 ± 10
AA + LTB4 1.6 ±1.2 138.3 ± 4.7
LTB4 + NDGA 1 ± 1.3 48.3 ± 1.7
AA + NDGA+ LTB4 2.3 ± 2.2 67.3 ±10.8
LTB4 + Zil 0.3 ±1.1 62.7± 5.8
AA + Zil + LTB4 2.6 ±1.5 68 ±12.4
AA + PGD2 4.3±1 62 ± 6.2
PGD2 + NDGA 2.3±1.5 44.3± 5.2
AA + NDGA+ PGD2 1.5 ±2.6 58.7 ±18.1
PGD2 + Zil 1.6±2.3 61.6 ±15.7
AA + Zil + PGD2 3.6 ± 1.2 43 ±14.8

Results shown here are the average values (± SD) obtained from migration assays after various treatments. The experiments were repeated twice in triplicate on two different days. SD, Standard deviation; LTB4, leukotriene B4; NDGA, nordihydroguaiaretic acid; PGD2, prostaglandin D2.